| Preface | 5 |
---|
| List of Contributors | 7 |
---|
| List of Contents | 8 |
---|
| Protein Kinase Inhibitors for the Treatment of Disease: The Promise and the Problems | 10 |
---|
| General Aspects of PKs Inhibition | 17 |
---|
| New Design Strategies for Ligands That Target Protein Kinase- Mediated Protein Protein Interactions | 18 |
| Pharmacological Potential and Inhibitors of Individual Classes of Protein Kinases | 52 |
---|
| The Paullones: A Family of Pharmacological Inhibitors of Cyclin- Dependent Kinases and Glycogen Synthase Kinase 3 | 53 |
| Pharmacological Potential of p38 MAPK Inhibitors | 71 |
| Inhibitors of PKA and Related Protein Kinases | 90 |
| Inhibitors of Protein Kinase CK2: Structural Aspects | 130 |
| Aminoglycoside Kinases and Antibiotic Resistance | 161 |
| Pharmacological Potential and Inhibitors of Individual Classes of Protein Phosphatases | 193 |
---|
| Protein Tyrosine Phosphatases as Therapeutic Targets | 194 |
| Structure-Based Design of Protein Tyrosine Phosphatase Inhibitors | 218 |
| Biological Validation of the CD45 Tyrosine Phosphatase as a Pharmaceutical Target | 266 |
| Serine/Threonine Protein Phosphatase Inhibitors with Antitumor Activity | 297 |
| Inhibitors in Clinical Use or Advanced Clinical Trials | 320 |
---|
| Clinical Immunosuppression using the Calcineurin- Inhibitors Ciclosporin and Tacrolimus | 321 |
| Targeted Therapy with Imatinib: An Exception or a Rule? | 360 |
| Clinical Aspects of Imatinib Therapy | 389 |
| Isoquinolinesulfonamide: A Specific Inhibitor of Rho-Kinase and the Clinical Aspect of Anti- Rho-Kinase Therapy | 409 |
| Discovery and Development of Iressa: The First in a New Class of Drugs Targeted at the Epidermal Growth Factor Receptor Tyrosine Kinase | 431 |
| Subject Index | 449 |